Verify Brand is pleased to announce that Kyowa Kirin International, formerly ProStrakan, a global virtual pharmaceutical manufacturer and subsidiary of Kyowa Hakko Kirin Co. Ltd, has selected Verify Brand as its serialization software solution provider to comply with the FDA's Drug Supply Chain and Security Act (DSCSA) and Europe's Falsified Medicines Directive (FMD) regulations.
Kyowa Kirin International, headquartered in the U.K., has made its name in the pharma industry by providing its patients with life-saving, high-quality products made from advanced production technology, with a special focus on oncology, nephology, immunology and allergy.
After vetting several serialization and track and trace software providers, Kyowa Kirin selected Minneapolis-based Verify Brand on the strength of its proven track and trace software and time-tested implementation and project management framework.
"During the project scoping stage, Verify Brand demonstrated professionalism and broad expertise, impressing upon us that they are at the forefront of global serialization," said, Kyowa Kirin supply chain manager, Dale Sullivan. "Verify Brand is extremely knowledgeable, proactive and comprehensive in their approach and we are confident we have made the correct decision."
In addition to helping Kyowa Kirin meet global regulatory compliance mandates, Verify Brand's serialization solution will allow the virtual pharmaceutical manufacturer to use the serialization data it captures to track each individual product through the supply chain while providing real-time insights and reports, such as inventory dwell times and product expiration alerts.
"We are looking forward to working with Kyowa Kirin on their serialization project," said Verify Brand CEO, Michael Howe. "Our SWIFT implementation framework will ensure a seamless and timely deployment, while our platform's suite of analytics will equip Kyowa Kirin with the tools to fully leverage its serialization data."